Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2023-04-19 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
关于注销2021年股票期权激励计划部分已授予股票期权的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of part of its 2021 stock option incentive plan. It details the board and supervisory approvals, legal opinions, and the impact of the cancellation on the company. The content focuses on stock option cancellations, which is related to share-based compensation and capital changes. It is not a full financial report, earnings release, or management discussion. It is also not a simple announcement of a report publication but a substantive announcement about share-based incentive plan changes. This fits best under the category of Share Issue/Capital Change (SHA), as it involves cancellation of granted stock options, which affects the company's capital structure and share incentives.
2023-04-19 Chinese
附件16：海通证券股份有限公司关于和元生物技术（上海）股份有限公司2022年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the 2022 annual verification of the storage and use of funds raised by Heyuan Biotechnology (Shanghai) Co., Ltd. It includes specific financial figures about the amount raised, usage, management, and regulatory compliance of the raised funds. The document references regulatory guidelines related to the management and use of raised funds, includes auditor opinions, and detailed tables of fund usage. This matches the characteristics of an Audit Report / Information (AR) as it is a standalone report focused on the audit and verification of the use of raised funds, not a full annual report or a simple announcement. The document length and detail confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-19 Chinese
海通证券股份有限公司关于和元生物技术（上海）股份有限公司继续使用暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Haitong Securities regarding Heyuan Biotechnology (Shanghai) Co., Ltd.'s continued use of temporarily idle raised funds for cash management. It references regulatory guidelines on the management and use of raised funds, details the amount and purpose of the raised funds, the investment products used for cash management, risk control measures, and approvals by the board, supervisory committee, independent directors, and the sponsor institution. The document is not a financial report like an annual or interim report, nor is it a simple announcement. It is a regulatory compliance and verification report related to the use of raised funds, which fits best under Regulatory Filings (RNS) as it does not constitute an audit report or capital update but is a regulatory disclosure and verification document.
2023-04-19 Chinese
《和元生物技术（上海）股份有限公司章程》（修订后）
Regulatory Filings
2023-04-19 Chinese
《股东大会议事规则》
Governance Information Classification · 100% confidence The document is titled '和元生物技术（上海）股份有限公司 股东大会议事规则', which translates to 'Rules of Procedure for the Shareholders' General Meeting of Heyuan Biotechnology (Shanghai) Co., Ltd.' The content extensively details the procedures, rules, and regulations governing the conduct of shareholders' meetings, including the rights and responsibilities of shareholders, voting procedures, meeting convocations, and resolutions. It does not contain financial statements, audit results, or earnings data. Instead, it is a governance document outlining internal rules related to shareholder meetings and corporate governance practices. Therefore, it fits best under the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, not just an announcement or summary, so it is not an RPA or RNS.
2023-04-19 Chinese
《监事会议事规则》
Governance Information Classification · 95% confidence The document is titled '监事会议事规则' which translates to 'Supervisory Board Rules' or 'Rules of Procedure for the Supervisory Board' of a company. It details the structure, duties, rights, meeting procedures, and responsibilities of the supervisory board members. It references relevant laws and company articles but does not contain financial data, audit results, or any report of financial performance. It is a governance document outlining internal rules and governance practices of the supervisory board. Therefore, it fits the category of Governance Information (CGR). The document length is about 4857 characters, which is consistent with a detailed governance rules document rather than a brief announcement or a financial report.
2023-04-19 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.